Lindsey Devisscher
Gent, VLG 9000, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 92 publications
Ultrashort-Chain Per- and Polyfluoroalkyl Substances and Cholestasis: In Vitro Evidence of Liver Dysfunction from Emerging Environmental Contaminants.
Journal: Environmental science & technology
Published: March 19, 2026
Harnessing human immune system models to validate NADPH oxidase 1 inhibition as treatment for hepatocellular carcinoma.
Journal: Frontiers in pharmacology
Published: February 10, 2026
Interleukin-8-driven monocyte activation in primary sclerosing cholangitis: Insights from single-cell analysis and humanized immune system mice.
Journal: JHEP reports : innovation in hepatology
Published: December 16, 2025
Tiny molecules, big concerns: ultrashort-chain PFAS on the regulatory radar.
Journal: Archives of toxicology
Published: July 15, 2025
Liver transplantation for hepatopulmonary syndrome: A systematic review and meta-analysis.
Journal: JHEP reports : innovation in hepatology
Published: May 02, 2025
In vitro test battery for testing molecular initiating events in chemical-induced cholestasis.
Journal: Toxicology
Published: February 18, 2025
Mitochondrial dysfunction characterises the multigenerational effects of maternal obesity on MASLD.
Journal: JHEP reports : innovation in hepatology
Published: January 27, 2025
Aleurone supplementation enhances the metabolic benefits of training in Standardbred mares: impacts on glucose-insulin dynamics and gut microbiome composition.
Journal: Frontiers in physiology
Published: January 22, 2025
The double-edged sword of metabolic and bariatric surgery: extending the biliary limb can trigger bacterial translocation, sepsis, and liver inflammation - an experimental study.
Journal: International journal of surgery (London, England)
Published: November 27, 2024
The pan-PPAR agonist lanifibranor reduces portal pressure independent of fibrosis reduction through the splanchnic vasculature.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 13, 2024
PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression.
PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression.
Journal: Metabolism: clinical and experimental
Published: October 15, 2024
Last Updated: 09/26/2026